SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Bitcoin is the world's first decentralized cryptocurrency, created in 2009 by the pseudonymous Satoshi Nakamoto. It enables peer-to-peer electronic cash transactions without intermediaries like banks or governments, operating on a blockchain secured by Proof of Work mining and the SHA-256 cryptographic algorithm.   With a fixed supply cap of 21 million coins and programmatic halvings every four years that reduce miner rewards, Bitcoin is designed as a deflationary digital asset often called "digital gold." Its value stems from solving the double-spending problem without trusted intermediaries, creating the first truly scarce digital asset with censorship resistance and permissionless access that no government, corporation, or individual can control.  Bitcoin operates as a decentralized peer-to-peer network where transactions are recorded on a public ledger called the blockchain, distributed across thousands of computers globally. Transactions are grouped into blocks added approximately every 10 minutes through mining, where specialized computers compete to solve complex mathematical puzzles.   Bitcoin has achieved mainstream adoption through multiple vectors. The January 2024 SEC approval of 11 spot Bitcoin ETFs opened Bitcoin investment to traditional finance participants, and corporations like Strategy (formerly MicroStrategy) are using Bitcoin as a treasury reserve asset to protect against currency debasement, offering MSTR holders amplified exposure to Bitcoin.   The Bitcoin ecosystem continues to evolve with innovations like Ordinals, which emerged in January 2023 to enable NFT-like functionality directly on Bitcoin, and BRC-20 tokens, an experimental standard for creating fungible tokens using Ordinal inscriptions. BTCFi (Bitcoin Finance) represents emerging financial applications extending beyond Bitcoin's traditional role, with protocols like Babylon allowing Bitcoin holders to stake BTC to secure Proof of Stake chains.

Bitcoin

Bitcoin is trending as investors debate whether current price action signals a breakout or another liquidity trap amid heavy short leverage and ongoing geopolitical uncertainty. The community is actively tracking large institutional inflows and Michael Saylor's ongoing accumulation strategy, while traders remain divided on whether this momentum can finally hold above key resistance levels.

Coinbase Global, Inc. engages in the provision of a trusted platform that serves as a compliant on-ramp to the onchain economy and enables users to engage in a wide variety of activities with their crypto assets in both proprietary and third-party product experiences enabled by access to decentralized applications. It offers consumers primary financial account for the cryptoeconomy, institutions a full-service prime brokerage platform with access to deep pools of liquidity across the crypto marketplace, and developers a suite of products granting access to build onchain. The company was founded by Brian Armstrong and Fred Ernest Ehrsam in May 2012 and is headquartered in New York, NY.

Coinbase Global Inc - Ordinary Shares - Class A

Coinbase Global Inc

Coinbase is surging as traders grow optimistic about progress on the Clarity Act, fueling speculation that clearer regulatory guidelines will catalyze institutional adoption and expand the company's role as a leading digital asset exchange. The community is actively debating the stock's correlation with Bitcoin's recent price action, with many using the current volatility to position themselves for a potential breakout toward prior resistance levels.

Strategy, Inc. engages in the provision of enterprise analytics and mobility software. The firm designs, develops, markets, and sells software platforms through licensing arrangements and cloud-based subscriptions and related services. Its product packages include Hyper. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Tysons Corner, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

MicroStrategy is experiencing heightened volatility and intense social media debate as investors weigh the company's aggressive and ongoing Bitcoin accumulation strategy against concerns regarding debt-funded dilution. Market participants are closely watching the stock's role as a levered proxy for Bitcoin, with sentiment split between those anticipating a major breakout tied to BTC price appreciation and others warning of unsustainable leverage and potential downside risks.

Avis Budget Group, Inc. engages in the provision of vehicle sharing and rental services. It operates through the Americas and International segments. The Americas segment includes vehicle rental and car sharing operations in North America, South America, Central America, and the Caribbean. The International segment is involved in vehicle rental and car sharing operations in Europe, the Middle East, Africa, Asia, and Australasia. The company was founded in 1946 and is headquartered in Parsippany, NJ.

Avis Budget Group Inc

Avis Budget Group (CAR) is currently experiencing an intense, parabolic short squeeze driven by an extreme supply-demand imbalance and highly concentrated institutional ownership. While the community is actively debating the sustainability of the stock's massive rally and the potential for regulatory or corporate intervention, retail traders are focused on the extreme volatility, high option premiums, and the ongoing battle between trapped short sellers and aggressive bulls.

Kyverna Therapeutics, Inc. is a cell therapy clinical-stage biotechnology company, which engages in the provision of treatments and potential cures for serious autoimmune diseases. The company was founded in June 2018 and is headquartered in Emeryville, CA.

Kyverna Therapeutics Inc.

Kyverna Therapeutics is surging following the release of positive registrational trial data for its CAR T-cell therapy, miv-cel, in treating Stiff Person Syndrome, with the company announcing plans for a BLA submission in early 2026. The community is buzzing over the therapy's potential as a 'first-in-class' treatment for autoimmune diseases, fueling speculation regarding a potential buyout or partnership given the firm's robust clinical results and large-scale manufacturing advancements.

Strive, Inc. engages in the provision of an asset management Bitcoin treasury. It is focused on maximizing value for shareholders, accumulating bitcoin and outperforming bitcoin over the long run. The company was founded by Arshia Sarkhani, Jackson Fairbanks, Arman Sarkhani, and Kyle Fairbanks on March 9, 2022 and is headquartered in Dallas, TX.

Strive Inc. - Ordinary Shares - Class A

Strive Inc.

Strive Inc. is currently attracting attention as a leveraged Bitcoin play, with investors closely watching the company's significant BTC holdings and the potential impact of its new digital credit ETF. The community is actively debating the company's long-term valuation and management strategies, balancing bullish sentiment regarding Bitcoin's future against concerns over past equity dilution and share performance.

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

Candel Therapeutics is capturing significant investor attention as the community anticipates critical upcoming prostate cancer data presentations at the American Urological Association conference. Shareholders are expressing strong bullish conviction, citing the company's platform potential and pipeline progress as key drivers for long-term value despite recent share price volatility.

Infinite Money Glitch ($IMG) is revolutionizing DeFi on Solana by leveraging the Token2022 program's advanced tax extension capabilities to create a truly innovative reward system for token holders.  At its core, $IMG implements a seamless 5% tax on all transactions - whether buying, selling, or transferring tokens. This tax is automatically collected and distributed to holders in SOL, creating a sustainable passive income stream for the community. 4.5% of the tax gets sent to holders, while .5% gets sent to an Infrastructure wallet to help with development, marketing and general infrastructure.  What sets $IMG apart is its implementation of Solana's Token2022 program, enabling automated and efficient reward distribution without relying on external smart contracts.

Infinite Money Glitch

The community behind $IMG is actively rallying around the token's passive Solana reward mechanism and upcoming technical updates, framing it as a resilient project with a battle-tested foundation. Enthusiasts are focusing on the asset's deflationary potential and the long-term utility of the 'infinite money glitch' concept, dismissing recent price volatility as a mere entry opportunity.

Dogelon Mars

Dogelon Mars continues to trend as investors speculate on potential synergies with Elon Musk's ventures and track the coin's historical meme status. Community sentiment remains polarized, with many holders focused on long-term accumulation and anticipation of future exchange listings, while others express frustration over stagnant price action and the lack of utility.

Dogecoin is an open-source digital currency based on the "Doge" meme that functions as a peer-to-peer medium for fast payments and digital tipping. Unlike projects backed by corporate entities, its value is driven by a global community, and the project is managed by a decentralized group of volunteers and the non-profit Dogecoin Foundation rather than a formal company.  Originally created in 2013 by software engineers Billy Markus and Jackson Palmer as a market parody, the project held no public sale or venture capital rounds. The network operates as a fork of LuckyCoin, which itself was a fork of Litecoin, using a proof of work consensus mechanism. It employs the Scrypt algorithm to ensure the mining process remains fast and efficient, with new blocks processed every 60 seconds. A unique technical feature is its use of merged mining, allowing miners to secure Dogecoin simultaneously with other Scrypt-based networks like Litecoin.  To keep transaction fees low and the network running indefinitely, Dogecoin features an uncapped supply where new coins are added forever. In a major regulatory milestone in March 2026, a joint SEC and CFTC framework officially classified Dogecoin as a digital commodity, placing it in the same asset category as gold or oil.

Dogecoin

Dogecoin is currently capturing investor attention as holders actively debate its future amid broader market volatility and speculation regarding potential integrations with major platforms. The community remains polarized, with many users focused on technical indicators and holding out hope for a breakout while others express frustration over stagnant price movement.

statis crypto Watchlist

Ethereum

Solana

Ripple

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Phathom Pharmaceuticals (NASDAQ:PHAT) Shares Down 6.8% - Time to Sell?

Phathom Pharmaceuticals (NASDAQ:PHAT) Trading Down 6.8% - Time to Sell...

Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Receives Consensus Rating of "Moderate Buy" from Analysts

Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT - Get Free Report) has received a consensus recommendation of "Moderate Buy" from the nine analysts that are presently covering the firm, MarketBeat.com...

Hennion & Walsh Asset Management Inc. Buys New Shares in Phathom Pharmaceuticals, Inc. $PHAT

Hennion & Walsh Asset Management Inc. bought a new position in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor bought 114,981 shares of the company's stock, valued at appro...

Phathom Pharmaceuticals (NASDAQ:PHAT) Shares Gap Up After Analyst Upgrade

Phathom Pharmaceuticals (NASDAQ:PHAT) Shares Gap Up on Analyst Upgrade...

Phathom Pharmaceuticals (NASDAQ:PHAT) Upgraded at Barclays

Barclays raised shares of Phathom Pharmaceuticals from an "equal weight" rating to an "overweight" rating and raised their target price for the stock from $16.00 to $18.00 in a report on Friday...

Ocugen Falls as Gene Therapy for Eye Disease Lags in Phase II Study

OCGN stock falls after phase II data for OCU410 show lower lesion reduction than earlier results, despite 31% improvement in the eye disease study.

ImmunityBio Rises on China Nod to Bladder Cancer Combo Therapy

IBRX stock jumps after China approves Anktiva combo therapy for bladder cancer, marking its first Asia nod and expanding global reach to 34 markets.

Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Given Average Recommendation of "Moderate Buy" by Brokerages

Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT - Get Free Report) has earned an average rating of "Moderate Buy" from the nine analysts that are currently covering the firm, Marketbeat reports. One...

Puma Biotechnology Stock Declines More Than 9% in a Month: Here's Why

PBYI stock drops over 9% as weak 2026 revenue guidance and heavy reliance on Nerlynx raise concerns despite modest sales growth.

Mirum Completes Enrollment in Late-Stage EXPAND Study of Livmarli

MIRM completes enrollment in phase III EXPAND study of Livmarli for treating additional rare cholestatic liver diseases. Top-line data due in Q4 2026.

Phathom Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel treatments for gastrointestinal diseases. The company was founded by Tadataka Yamada, David Socks, Azmi Nabulsi, Aditya Kohli, and Roger Ulrich on January 9, 2018 and is headquartered in Florham Park, NJ.

PHAT
Phathom Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest PHAT News

PHATPhathom Pharmaceuticals Inc